Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Accell Plus is a demineralized bone matrix (DBM) putty developed by Integra LifeSciences for use as a bone graft substitute in orthopedic and spinal surgeries. It is composed of a combination of demineralized bone matrix and the proprietary Accell Bone Matrix (ABM), which is a more soluble and dispersed form of DBM. This formulation is designed to maximize the surface area of the bone-derived growth factors, particularly bone morphogenetic proteins (BMPs), thereby enhancing the product's osteoinductive potential. Accell Plus provides an osteoconductive scaffold that supports the attachment and proliferation of osteogenic cells while simultaneously inducing the differentiation of mesenchymal stem cells into bone-forming osteoblasts. It is primarily indicated for filling bone voids or gaps that are not intrinsic to the stability of the bony structure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Accell Plus.